Novelix Pharmaceuticals Ltd
₹ 75.8
-5.00%
19 Jun
- close price
About
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]
Key Points
- Market Cap ₹ 181 Cr.
- Current Price ₹ 75.8
- High / Low ₹ 92.0 / 29.3
- Stock P/E 70.8
- Book Value ₹ 22.0
- Dividend Yield 0.00 %
- ROCE 9.98 %
- ROE 8.00 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Promoter holding has increased by 4.06% over last quarter.
- Company's median sales growth is 42.1% of last 10 years
- Company's working capital requirements have reduced from 222 days to 122 days
Cons
- Stock is trading at 3.44 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.12% over last 3 years.
- Company has high debtors of 163 days.
- Promoter holding has decreased over last 3 years: -16.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 4 | 3 | 4 | 2 | 1 | 1 | 2 | 4 | 31 | 132 | |
| 1 | 1 | 3 | 3 | 3 | 1 | 4 | 3 | 2 | 4 | 31 | 129 | |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | 0 | -0 | 0 | 3 |
| OPM % | 33% | 43% | 5% | 15% | 6% | 12% | -244% | -151% | 0% | -6% | 0% | 3% |
| 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | -0 | 0 | 0 | 3 |
| Tax % | 88% | 31% | 24% | 34% | -32% | 20% | 0% | -1% | 0% | 50% | 33% | 25% |
| 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | -0 | 0 | 0 | 3 | |
| EPS in Rs | 0.02 | 0.12 | 0.19 | 0.22 | 0.31 | 0.11 | -4.04 | -1.93 | -0.07 | 0.01 | 0.08 | 1.21 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 63% |
| 5 Years: | 152% |
| 3 Years: | 310% |
| TTM: | 331% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 23% |
| 3 Years: | 255% |
| TTM: | 3100% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 53% |
| 3 Years: | 100% |
| 1 Year: | 159% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 2% |
| 3 Years: | 5% |
| Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 21 |
| Reserves | 3 | 3 | 3 | 4 | 4 | 4 | 1 | -1 | -1 | -1 | 8 | 25 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 42 | |
| Total Liabilities | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 92 |
| 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 3 | 2 | 3 | 3 | 4 | 4 | 1 | 3 | 3 | 0 | 0 |
| 9 | 8 | 9 | 9 | 9 | 8 | 5 | 5 | 4 | 4 | 27 | 89 | |
| Total Assets | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 92 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | 2 | -1 | 1 | -0 | 1 | 1 | 1 | -2 | -0 | -14 | -22 | |
| -0 | -2 | 1 | -1 | 0 | -0 | 0 | 0 | 0 | 0 | 3 | -2 | |
| -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 26 | |
| Net Cash Flow | -1 | 0 | -0 | -0 | 0 | 1 | 1 | 1 | -2 | -0 | 1 | 2 |
| Free Cash Flow | -1 | 2 | -1 | 1 | -0 | 1 | 0 | -1 | -2 | -0 | -14 | -26 |
| CFO/OP | -90% | 472% | -535% | 225% | -220% | 672% | -18% | -34% | 136% | -9,771% | -643% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 30 | 4 | 40 | 130 | 216 | 19 | 25 | 32 | 36 | 1 | 216 | 163 |
| Inventory Days | 0 | 28 | 19 | 13 | 39 | 89 | 239 | 222 | 113 | 10 | 42 | |
| Days Payable | 0 | 54 | 13 | 5 | 4 | 0 | 14 | 0 | 115 | 116 | ||
| Cash Conversion Cycle | 30 | 4 | 68 | 95 | 216 | 54 | 111 | 271 | 244 | 114 | 111 | 88 |
| Working Capital Days | 2,225 | 2,584 | 863 | 932 | 858 | 1,711 | 819 | 647 | 743 | 346 | 197 | 122 |
| ROCE % | 1% | 1% | 1% | 3% | 1% | 1% | -31% | -19% | -1% | 0% | 1% | 10% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Business Segments Number |
|
|||||||||
| Revenue contribution from Sale of Pharmaceuticals INR in '000s |
||||||||||
| Number of Permanent Employees Number |
||||||||||
| Trade Payables Turnover Ratio Times |
||||||||||
| Trade Receivables Turnover Ratio Times |
||||||||||
| Contribution of Interest Income to Turnover Percentage |
||||||||||
| Contribution of Trading in Food Products to Turnover Percentage |
||||||||||
| Number of R&D Labs Allotted Number |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Submission of newspaper publication of corrigendum to the EGM Notice.
-
Shareholders Meeting- Corrigendum To The EGM Notice Of The EGM Scheduled To Be Held On 01St July, 2026.
17 Jun - Corrigendum to EGM notice revises 12,00,000-share preferential allotment, disqualifying two allottees and reallocating shares.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Jun - Newspaper Publication for intimation of special window.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 10 Jun
-
Shareholders Meeting- Notice Of Extra-Ordinary General Meeting Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
9 Jun - EGM on July 1, 2026 to approve 12 lakh equity shares at Rs.57, raising Rs.6.84 crore.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
NPL is a recent entrant in the life sciences research and pharmaceutical intermediates business. In FY24, the company altered its objectives to expand into the pharmaceutical bulk drug segment and healthcare research, analytics, and technology. Currently, it is engaged in pharmaceutical research and the production and trading of bulk drugs (Active Pharmaceutical Ingredients) as well as key starting materials and intermediates.